Brain tumors: full- and half-dose contrast-enhanced MR imaging at 3.0 T compared with 1.5 T--Initial Experience.
To prospectively and intraindividually compare the effect of magnetic resonance (MR) imaging at a higher magnetic field strength (3.0 T) on contrast-to-noise ratio (CNR) at different doses of a T1-shortening contrast agent in patients with contrast-enhancing brain lesions, with 1.5-T MR imaging as a reference standard. Institutional review board approval and informed consent were obtained for all patient and volunteer studies. Twelve patients (six women, six men; mean age, 58 years; range, 29-76 years) with 12 enhancing brain lesions (11 patients with primary brain tumors and one with a solitary cerebral metastasis) underwent contrast material-enhanced MR imaging three times, on three separate days: once at 1.5 T with a full dose of 0.10 mmol/kg gadopentetate dimeglumine, once at 3.0 T with a full dose, and once at 3.0 T with half that dose, 0.05 mmol/kg. The same contrast-enhanced T1-weighted spin-echo images (repetition time msec/echo time msec, 500/12; section thickness, 5 mm; matrix, 256 x 205) were obtained at both 3.0 T and 1.5 T after prior optimization of parameters at 3.0 T. The number and conspicuity of enhancing brain lesions were assessed with blinded clinical image reading. Signal-to-noise ratio and CNR were determined with region of interest analysis of enhancing lesions and normal contralateral white matter. For 3.0 T with half the standard dose and with the full dose, CNR of lesions was intraindividually compared with CNR at 1.5 T with the full dose by using the Wilcoxon matched-pairs signed rank test. At 3.0 T and full dose, CNR was 2.8-fold higher than that at 1.5 T and full dose (P < .001). At the same time, higher lesion conspicuity at clinical image reading was observed. With only half the standard dose, MR imaging at 3.0 T still yielded higher CNR (1.3-fold higher) than that with full dose at 1.5 T (P < .01). With the same amount of contrast agent, MR imaging at 3.0 T offered a significantly higher CNR of enhancing cerebral lesions, compared with that at 1.5 T; even with the dose reduced by half, CNR was still higher at 3.0 T.